Home > Resources > Whitepapers > BREAST CANCER DRUGS FUNDING AND TRIALS

BREAST CANCER DRUGS FUNDING AND TRIALS

August 1, 2017

This white paper arises out of the Pink Ribbon drugs funding & trials conference, held at the faculty of pharmaceutical medicine on 23 March 2017 (full programme provided on page 13-15). The general theme to emerge from the conference is that the UK would benefit from enhanced communication between:
• Pharma, regulators and NICE to expedite drug and pricing approval;
• Regulators, NICE and hospitals to allow hospitals time to prepare for new drugs, for example through horizon scanning, with transparency on costs, efficacy and safety profile;
• Pharma and trials database creators, for example, Cancer Research UK (CRUK), to ensure information on clinical trials is effectively disseminated to those patients who may wish to take part – for the benefit of the patients themselves, as well as the national health service (NHS) and pharma.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

Central Maine Healthcare

An integrated healthcare delivery system, Central Maine Healthcare (CMH) serves 400,000 people in the central, western, and mid-coast regions of the state. One flagship medical center, two rural, critical access hospitals and an extensive variety of primary and specialty care practices located in 14 communities throughout the region make up the CMH system. Central Maine Healthcare is focused on exceptional quality and patient access to care. Affiliated with Mass General Hospital in Boston, CMH provides Mainers the most innovative and current treatments available without having to leave their hometown. The Mass General affiliation gives CMH patients greater access to sub-specialty care in hematology/oncology, neurology, stroke, and trauma.

OTHER WHITEPAPERS
news image

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.

Read More
news image

MOLECULAR GLUES LANDSCAPE IN DRUG DISCOVERY

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

Read More
news image

The SwedishDrug Discovery and DevelopmentPipeline 2023

whitePaper | March 23, 2023

Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.

Read More
news image

BUILDING A TOMORROW-READY LAB

whitePaper | September 8, 2022

Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.

Read More
news image

Determine the right dust collection equipment for tablet press applications

whitePaper | October 13, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical. The dust collector linked to the press can contribute to reliable, consistent performance

Read More
news image

Learning from the COVID-19 Policy Response

whitePaper | November 3, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result of a collaborative process facilitated and endorsed by the World Economic.

Read More

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.

Read More

MOLECULAR GLUES LANDSCAPE IN DRUG DISCOVERY

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

Read More

The SwedishDrug Discovery and DevelopmentPipeline 2023

whitePaper | March 23, 2023

Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.

Read More

BUILDING A TOMORROW-READY LAB

whitePaper | September 8, 2022

Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.

Read More

Determine the right dust collection equipment for tablet press applications

whitePaper | October 13, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical. The dust collector linked to the press can contribute to reliable, consistent performance

Read More

Learning from the COVID-19 Policy Response

whitePaper | November 3, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result of a collaborative process facilitated and endorsed by the World Economic.

Read More
More Whitepapers

Spotlight

Central Maine Healthcare

An integrated healthcare delivery system, Central Maine Healthcare (CMH) serves 400,000 people in the central, western, and mid-coast regions of the state. One flagship medical center, two rural, critical access hospitals and an extensive variety of primary and specialty care practices located in 14 communities throughout the region make up the CMH system. Central Maine Healthcare is focused on exceptional quality and patient access to care. Affiliated with Mass General Hospital in Boston, CMH provides Mainers the most innovative and current treatments available without having to leave their hometown. The Mass General affiliation gives CMH patients greater access to sub-specialty care in hematology/oncology, neurology, stroke, and trauma.

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference